Filtered By:
Source: Circulation
Condition: Bleeding
This page shows you your search results in order of date.
Order by Relevance | Date
Total 151 results found since Jan 2013.
Associations of Apixaban Dose With Safety and Effectiveness Outcomes in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease
CONCLUSIONS: Compared with 2.5 mg, use of 5 mg apixaban was associated with a higher risk of bleeding in patients with atrial fibrillation and severe chronic kidney disease, with no difference in the risk of stroke/systemic embolism or death, supporting the apixaban dosing recommendations on the basis of kidney function by the European Medicines Agency, which differ from those issued by the US Food and Drug Administration.PMID:37681341 | DOI:10.1161/CIRCULATIONAHA.123.065614
Source: Circulation - September 8, 2023 Category: Cardiology Authors: Yunwen Xu Alex R Chang Lesley A Inker Mara McAdams-DeMarco Morgan E Grams Jung-Im Shin Source Type: research
Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction in STREAM-2: A Randomized, Open-Label Trial
CONCLUSIONS: Halving the dose of tenecteplase in a pharmaco-invasive strategy in this early-presenting, older STEMI population was associated with electrocardiographic changes that were at least comparable to those after primary PCI. Similar clinical efficacy and angiographic end points occurred in both treatment groups. The risk of intracranial hemorrhage was higher with half-dose tenecteplase than with primary PCI. If timely PCI is unavailable, this pharmaco-invasive strategy is a reasonable alternative, provided that contraindications to fibrinolysis are observed and excess anticoagulation is avoided.REGISTRATION: URL: ...
Source: Circulation - July 13, 2023 Category: Cardiology Authors: Frans Van de Werf Arsen D Risti ć Oleg V Averkov Alexandra AriasMendoza Yves Lambert Jos é F Kerr Saraiva Pablo Sepulveda Fernando Rosell-Ortiz John K French Ljilja B Musi ć Katleen Vandenberghe Kris Bogaerts Cynthia M Westerhout Alain Pag ès Thierry Source Type: research
Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial
CONCLUSIONS: The study was terminated prematurely after enrollment of 32% of planned accrual because of recruitment challenges and lower-than-expected event rate. Rivaroxaban prescribed for 35 days in nonhospitalized patients with symptomatic COVID-19 at risk for thrombosis did not appear to reduce a composite end point of venous and arterial thrombotic events, hospitalization, and death.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT04508023.PMID:37154020 | DOI:10.1161/CIRCULATIONAHA.123.063901
Source: Circulation - May 8, 2023 Category: Cardiology Authors: Gregory Piazza Alex C Spyropoulos Judith Hsia Mark Goldin William J Towner Alan S Go Todd M Bull Stephen Weng Concetta Lipardi Elliot S Barnathan Marc P Bonaca PREVENT-HD Investigators Source Type: research
Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF
CONCLUSIONS: Standard-dose DOACs are safer and more effective than warfarin down to a CrCl of at least 25 mL/min. Lower-dose DOACs do not significantly lower the incidence of bleeding or ICH compared with standard-dose DOACs but are associated with a higher incidence of S/SE and death. These findings support the use of standard-dose DOACs over warfarin in patients with kidney dysfunction.PMID:37042255 | DOI:10.1161/CIRCULATIONAHA.122.062752
Source: Circulation - April 12, 2023 Category: Cardiology Authors: Josephine Harrington Anthony P Carnicelli Kaiyuan Hua Lars Wallentin Manesh R Patel Stefan H Hohnloser Robert P Giugliano Keith A A Fox Ziad Hijazi Renato D Lopes Sean D Pokorney Hwanhee Hong Christopher B Granger Source Type: research
Pharmacology and Clinical Development of Factor XI Inhibitors
This article reviews the rationale, pharmacology, results of medium or small phase 2 studies, and future perspectives of drugs inhibiting FXI.PMID:36913497 | DOI:10.1161/CIRCULATIONAHA.122.062353
Source: Circulation - March 13, 2023 Category: Cardiology Authors: Antonio Greco Claudio Laudani Marco Spagnolo Federica Agnello Denise Cristiana Faro Simone Finocchiaro Marco Legnazzi Maria Sara Mauro Placido Maria Mazzone Giovanni Occhipinti Carla Rochira Lorenzo Scalia Davide Capodanno Source Type: research
Comparative Effectiveness of Left Atrial Appendage Occlusion Versus Oral Anticoagulation by Sex
CONCLUSIONS: In a real-world population of older Medicare beneficiaries with AF, compared with anticoagulation, LAAO was associated with a reduction in the risk of death, stroke, and long-term bleeding among women and men. These findings should be incorporated into shared decision-making with patients considering strategies for reduction in AF-related stroke.PMID:36780379 | DOI:10.1161/CIRCULATIONAHA.122.062765
Source: Circulation - February 13, 2023 Category: Cardiology Authors: Emily P Zeitler Stephen Kearing Megan Coylewright Devi Nair Jonathan C Hsu Douglas Darden A James O'Malley Andrea M Russo Sana M Al-Khatib Source Type: research
